Aura Biosciences, Inc. (NASDAQ:AURA) CFO Julie B. Feder Sells 25,131 Shares

Aura Biosciences, Inc. (NASDAQ:AURA) CFO Julie B. Feder sold 25,131 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $12.03, for a total transaction of $302,325.93. Following the completion of the sale, the chief financial officer now owns 134,276 shares in the company, valued at approximately $1,615,340.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Aura Biosciences Stock Down 2.2 %

AURA opened at $11.39 on Wednesday. The firm has a market cap of $564.29 million, a price-to-earnings ratio of -6.12 and a beta of 0.37. Aura Biosciences, Inc. has a fifty-two week low of $5.99 and a fifty-two week high of $12.38. The company’s 50-day moving average price is $8.80 and its 200 day moving average price is $8.13.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.04. Research analysts anticipate that Aura Biosciences, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. BTIG Research upped their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Scotiabank upped their target price on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Friday, October 18th. HC Wainwright upped their target price on shares of Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Cowen restated a “buy” rating on shares of Aura Biosciences in a research note on Friday. Finally, Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $23.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. American International Group Inc. boosted its holdings in shares of Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after acquiring an additional 3,782 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Aura Biosciences by 14.6% in the second quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after acquiring an additional 8,194 shares in the last quarter. Levin Capital Strategies L.P. boosted its holdings in shares of Aura Biosciences by 11.2% in the first quarter. Levin Capital Strategies L.P. now owns 111,200 shares of the company’s stock valued at $873,000 after acquiring an additional 11,200 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Aura Biosciences by 26.3% in the second quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock valued at $545,000 after acquiring an additional 15,000 shares in the last quarter. Finally, American Century Companies Inc. bought a new position in shares of Aura Biosciences in the second quarter valued at approximately $119,000. 96.75% of the stock is currently owned by institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.